HIV Infections Clinical Trial
Official title:
Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples
To assess the acceptability of and participation in a group counseling intervention,
including an assessment of willingness to disclose serostatus to a regular sexual partner
and the willingness of that partner to participate. To evaluate the profile of adverse
experiences (social, psychological, and physical harms) of individuals resulting from
participation in counseling and testing and attempts to initiate condom use within a stable
HIV serodiscordant partnership. To assess the potential for the intervention to result in
increased condom use among stable sexual partners.
There is a significant risk of HIV transmission to HIV-uninfected partners in HIV-discordant
couples. While condom use has been a major component of most AIDS prevention programs since
the mid-1980s, there has been little emphasis on promoting condom use within stable
partnerships. The most effective way to promote condom use among discordant couples remains
largely unknown.
Status | Completed |
Enrollment | 90 |
Est. completion date | July 1999 |
Est. primary completion date | July 1999 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria Volunteers must be: - HIV-positive through HIVNET testing or HIV-seronegative by EIA. - Presently in a sexual relationship of at least 6 months duration with the intention to remain with this partner for the duration of the study. - Willing to identify and recruit this sexual partner to which he/she has disclosed or will disclose HIV serostatus. - Willing to receive counseling and HIV testing (HIV-seronegative partners only). - Willing to agree to be interviewed with their partner and individually. - Willing to continue engaging in sex with their partner. - Willing to participate in a couples-based condom promotion intervention. - Willing and able to attend each scheduled intervention/follow-up study visit. Exclusion Criteria Volunteers with the following are excluded: - History of domestic violence. - Current consistent condom use. |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess acceptability and participation | Throughout study | No | |
Primary | Assess the potential for the intervention to result in increased condom use among stable sexual partners | Throughout study | No | |
Secondary | Assessment of willingness to disclose serostatus to a regular sexual partner and the willingness of that partner to participate | Throughout study | No | |
Secondary | Evaluation of adverse experiences (social, psychological, and physical harms) of individuals resulting from participation in counseling and testing | Throughout study | Yes | |
Secondary | Evaluation of attempts to initiate condom use within a stable HIV serodiscordant partnership | Throughout study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |